TICKERNERD
Menu
ABCLABCLHealthcare · Biotechnology

ABCL Stock Forecast: AbCellera Biologics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$11
+4.16% on the day

The 9 Wall Street analysts covering AbCellera Biologics, Inc. hold a median 12-month price target of $15 — +37.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 10 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$3.4B
Ticker Nerd rank
71 / 100
Median analyst target
$15
Analysts covering
9
Revenue$4.0M−76.3% y/y
Operating income−$58.9M
Net income−$55.4M
Free cash flow$23.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.8%
1M
+11.6%
YTD
+218.6%
1Y
+136.3%
From 52W high
−12.8%
From 52W low
+291.9%
$3
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABCL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AbCellera Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Growth
83
Accruals
67
Issuance
64
Value
60
Revisions
56
Quality
45
Size
29
Volatility
26

Momentum (94): The shares have been drifting up relative to others.

Volatility (26): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABCL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABCL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26ABCLHigh $30Median $15Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $9Median $15High $30

The green dot is the last close — the median target sits +37.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Truist SecuritiesMaintainsBuy$12 → $30
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$11 → $12
6 Aug 2026StifelMaintainsBuy$8.00 → $9.00
7 July 2026BenchmarkUpgradeBuy—
7 July 2026BenchmarkUpgradeBuy$11
5 May 2026Cantor FitzgeraldInitiatesOverweight—
10 Apr 2026Jones TradingInitiatesBuy—
7 Nov 2025Leerink PartnersDowngradeMarket Perform—
8 Aug 2025StifelMaintainsBuy—
14 July 2025KeybancMaintainsOverweight—
7 July 2025Leerink PartnersAssumesOutperform$5.00
16 May 2025Truist SecuritiesMaintainsBuy—
9 May 2025StifelMaintainsBuy—
16 Apr 2025KeybancMaintainsOverweight—
3 Mar 2025BenchmarkReiteratesHold—
28 Feb 2025StifelMaintainsBuy—
8 Jan 2025KeybancMaintainsOverweight—
5 Nov 2024BenchmarkReiteratesHold—
5 Nov 2024StifelReiteratesBuy—
20 Aug 2024BenchmarkDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABCL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABCL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, AbCellera Biologics, Inc. returned +136.3% against +17.5% for the S&P 500, dividends included.

ABCL vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Oct 25Jan 26Apr 26Jul 26ABCLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABCL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

AbCellera Biologics, Inc. (ABCL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.3×

Cheaper than 96% of US stocks

Price / sales
51.2×

Cheaper than 5% of US stocks

Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
−14.9×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−76.3%

Higher than 3% of US stocks

Earnings growth (YoY)
−76.3%

Higher than 5% of US stocks

Gross margin
—
Operating margin
−1550.0%

Higher than 5% of US stocks

Net margin
−248.8%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−17.3%

Higher than 32% of US stocks

Return on assets
−10.4%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AbCellera Biologics, Inc. (ABCL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AbCellera Biologics, Inc. has a market value of $3.4B and an enterprise value of $3.0B.

  • Revenue in the twelve months to 30 June 2026: $66.2M. The latest quarter shrank 76.3% year on year.

  • Net income over the same four quarters: −$164.7M, a −248.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$119.7M.

  • Shares outstanding: 306.5M.

  • Trailing P/E: −21.3×; forward P/E: −14.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • AbCellera Biologics, Inc. employs 562 people — $118K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

ABCL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABCLAbCellera Biologics, Inc.$3.4B
71
DYNDyne Therapeutics, Inc.$3.4B
24
DNLIDenali Therapeutics, Inc.$3.3B
59
TARSTarsus Pharmaceuticals, Inc.$3.5B
83
IDYAIDEAYA Biosciences, Inc.$3.5B
81
RCUSArcus Biosciences, Inc.$3.2B
59
IOVAIovance Biotherapeutics, Inc.$3.6B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AbCellera Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABCL news & analysis

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

Business Wire · 2 Sept 2026neutral

AbCellera Biologics announced it will present at the Cantor Global Healthcare Conference on September 9, 2026. The announcement was made via Business Wire from the company's Vancouver headquarters.

Why it matters — AbCellera watchers would care because the conference presentation gives investors an opportunity to hear from the company's leadership and gain exposure to its updates in a public healthcare industry forum.

What'sGoing On With AbCellera Biologics Stock On Tuesday?

Benzinga · 25 Aug 2026positive

AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday, with the stock up over 250% year-to-date according to Benzinga.

Why it matters — The notable year-to-date gain signals significant investor interest and momentum in the company's stock for ABCL watchers.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Seeking Alpha · 17 Aug 2026positive

The article argues that biotech stocks, especially small caps, are experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Why it matters — As a small-cap biotech company, ABCL could be affected by the improving capital flows, M&A activity, and renewed investor confidence in the biotech sector described in this piece.

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Business Wire · 13 Aug 2026positive

AbCellera announced the pricing of an oversubscribed $200 million public offering of common shares and pre-funded warrants. The offering, based in Vancouver, was announced through Business Wire for the ticker ABCL.

Why it matters — The pricing of an oversubscribed $200 million offering is notable for ABCL watchers as it indicates investor demand and provides the company with additional capital.

What's Going on With AbCellera Biologics Stock On Wednesday?

Benzinga · 12 Aug 2026positive

AbCellera Biologics shares rose Wednesday after the company announced positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.

Why it matters — The positive Phase 2 results for ABCL635 represent a key clinical milestone for AbCellera's pipeline and could open a significant new market opportunity if the treatment advances successfully.

FAQ

Frequently asked questions about ABCL stock

What is the ABCL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering AbCellera Biologics, Inc. have a median 12-month price target of $15, with estimates ranging from $9 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABCL stock a buy right now?

Of the 9 analysts covering AbCellera Biologics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AbCellera Biologics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABCL?

As at 10 Sept 2026, AbCellera Biologics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will ABCL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +37.7% from the last close, and Ticker Nerd's factor model ranks AbCellera Biologics, Inc. 71 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABCL stock forecast for 2030?

No analyst covering AbCellera Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABCL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $30 over the next 12 months.

How has ABCL stock performed over the past year?

AbCellera Biologics, Inc. returned +136.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbCellera Biologics, Inc. do?

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines.

What is the latest news on ABCL?

The most recent item we track (Business Wire, 2 Sept 2026): "AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026". AbCellera Biologics announced it will present at the Cantor Global Healthcare Conference on September 9, 2026. The announcement was made via Business Wire from the company's Vancouver headquarters.

Company

About AbCellera Biologics, Inc.

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines. Its platform combines biology, computation, engineering, and data science to identify rare and potent antibodies from natural immune responses and advance them into drug programs. The company’s current work spans endocrinology and women’s health, immunology, oncology, and inflammation-related diseases, reflecting a broad therapeutic focus. AbCellera Biologics Inc. also develops an internal pipeline of antibody candidates and collaborates with biopharmaceutical partners on discovery and development programs. Its capabilities extend from target identification and antibody discovery through clinical manufacturing support, making it an integrated player in the antibody therapeutics market.

CEO Dr. Carl L.G. Hansen Ph.D. · 562 employees · Canada · https://www.abcellera.com